Active Receptor Tyrosine Protein Kinase erbB-2 (ErbB2)
CD340; EGFR2; HER-2/neu; HER2; NEU; MLN 19; NGL; TKR1; p185; Epidermal Growth Factor Receptor 2; V-Erb-B2 Erythroblastic Leukemia Viral Oncogene Homolog 2; Neuro/Glioblastoma Derived Oncogene Homolog
- Product No.APB867Hu01
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
- Traits Freeze-dried powder
- Purity> 95%
- Isoelectric Point5.9
- ApplicationsCell culture; Activity Assays.
- DownloadInstruction Manual
- UOM 10µg50µg 200µg 1mg 5mg
For more details, please contact local distributors! US$ 720
For more details, please contact local distributors! US$ 1440
For more details, please contact local distributors! US$ 4320
For more details, please contact local distributors! US$ 10800
For more details, please contact local distributors!
Figure. The binding activity of EGRF2 with ACTb.
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. Epidermal growth factor receptor 2 (EGFR2) is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. The EGFR is essential for ductal development of the mammary glands, and agonists of the EGFR such as amphiregulin, TGF-α, and heregulin induce both ductal and lobuloalveolar development even in the absence of estrogen and progesterone. Besides, Actin Beta (ACTb) has been identified as an interactor of EGFR2, thus a binding ELISA assay was conducted to detect the interaction of recombinant human EGFR2 and recombinant human ACTb. Briefly, EGFR2 were diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to ACTb-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-EGFR2 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of EGFR2 and ACTb was shown in Figure 1, and this effect was in a dose dependent manner.
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
- BCA Protein Quantification Kit
- Monoclonal Antibody Customized Service
- Polyclonal Antibody Customized Service
- Protein Activity Test Experiment Service
- Electrophoretic Mobility Shift Assay (EMSA) Experiment Service
- Lentivirus Packaging Experiment Service
- Adenovirus Packaging Experiment Service
- Real Time PCR Experimental Service
|Neuroscience Letter||Therapeutic effect of co-transplantation of neuregulin 1-transfected-Schwann cells and bone marrow stromal cells on spinal cord hemisection syndrom Cyagen: source|